Download PDF
Semin Thromb Hemost 2014; 40(03): 313-318
DOI: 10.1055/s-0034-1370769
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Adverse Impact of Venous Thromboembolism on Patients with Cancer

Mili Arora
1   Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California
,
Ted Wun
1   Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California
2   Department of Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, California
3   Section of Hematology and Oncology, VA Northern California Health Care System, Mather, California
4   Clinical and Translational Science Center, UC Davis School of Medicine, Sacramento, California
› Author Affiliations
Further Information

Publication History

Publication Date:
05 March 2014 (online)

    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.

Keywords

venous thromboembolism - cancer - chemotherapy - anticoagulation - survival - bleeding
 

  • References

  • 1 Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29 (3) 316-320
    CrossrefPubMedGoogle Scholar
  • 2 Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 626-630
    PubMedGoogle Scholar
  • 3 McMahon BJ, Kwaan HC. Thrombotic and bleeding complications associated with chemotherapy. Semin Thromb Hemost 2012; 38 (8) 808-817
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost 2012; 38 (8) 768-779
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (4) 692-699
    CrossrefPubMedGoogle Scholar
  • 6 Trujillo-Santos J, Monreal M. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the Registro Informatizado de la Enfermedad Trombo Embólica Registry. Curr Opin Pulm Med 2012; 18 (5) 393-398
    CrossrefPubMedGoogle Scholar
  • 7 Levitan N, Dowlati A, Remick SC , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (5) 285-291
    CrossrefPubMedGoogle Scholar
  • 8 Prandoni P, Lensing AW, Piccioli A , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 9 Trujillo-Santos J, Nieto JA, Tiberio G , et al; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (3) 435-439
    PubMedGoogle Scholar
  • 10 Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25 (2) 173-182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013; 122 (11) 1873-1880
    CrossrefPubMedGoogle Scholar
  • 12 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 13 Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003; 98 (7) 1514-1520
    CrossrefPubMedGoogle Scholar
  • 14 Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer 2012; 118 (14) 3468-3476
    CrossrefPubMedGoogle Scholar
  • 15 Hanna DL, White RH, Wun T. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol 2013; 88 (1) 19-29
    CrossrefPubMedGoogle Scholar
  • 16 Wun T, White RH. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res 2010; 125 (Suppl. 02) S96-S102
    CrossrefPubMedGoogle Scholar
  • 17 Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013; 122 (14) 2310-2317
    CrossrefPubMedGoogle Scholar
  • 18 Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106 (13) 4027-4033
    CrossrefPubMedGoogle Scholar
  • 19 Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21 (18) 3542 , author reply 3543
    CrossrefPubMedGoogle Scholar
  • 20 Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res 2012; 129 (Suppl. 01) S85-S87
    CrossrefPubMedGoogle Scholar
  • 21 Buyck HC, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin. Clin Oncol (R Coll Radiol) 2003; 15 (5) 297
    CrossrefPubMedGoogle Scholar
  • 22 Giunta G. Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report. Case Rep Med 2010; 2010: 426804
    PubMedGoogle Scholar
  • 23 Isaacs K, Haim N. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. J Chemother 2005; 17 (3) 339-342
    CrossrefPubMedGoogle Scholar
  • 24 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 25 Anderson LA, Moore SC, Gridley G, Stone BJ, Landgren O. Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma 2011; 52 (5) 764-770
    CrossrefPubMedGoogle Scholar
  • 26 Amer MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res 2013; 5: 165-178
    PubMedGoogle Scholar
  • 27 Trujillo-Santos J, Casas JM, Casado I , et al; RIETE Investigators. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2011; 127 (Suppl. 03) S1-S4
    PubMedGoogle Scholar
  • 28 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (4) 458-464
    CrossrefPubMedGoogle Scholar
  • 29 Alcalay A, Wun T, Khatri V , et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24 (7) 1112-1118
    CrossrefPubMedGoogle Scholar
  • 30 Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6 (4) 601-608
    CrossrefPubMedGoogle Scholar
  • 31 Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25 (1) 70-76
    PubMedGoogle Scholar
  • 32 Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007; 105 (3) 784-790
    CrossrefPubMedGoogle Scholar
  • 33 Semrad TJ, O'Donnell R, Wun T , et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106 (4) 601-608
    CrossrefPubMedGoogle Scholar
  • 34 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
    CrossrefPubMedGoogle Scholar
  • 35 Zwicker JI, Liebman HA, Neuberg D , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
    CrossrefPubMedGoogle Scholar
  • 36 Koizume S, Jin MS, Miyagi E , et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66 (19) 9453-9460
    CrossrefPubMedGoogle Scholar
  • 37 Ruf W. Tissue factor and cancer. Thromb Res 2012; 130 (Suppl. 01) S84-S87
    CrossrefPubMedGoogle Scholar
  • 38 Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011; 9 (Suppl. 01) 306-315
    CrossrefPubMedGoogle Scholar
  • 39 Rydén L, Grabau D, Schaffner F, Jönsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010; 126 (10) 2330-2340
    PubMedGoogle Scholar
  • 40 Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008; 34 (2) 147-153
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Levine M, Hirsh J, Gent M , et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343 (8902) 886-889
    CrossrefPubMedGoogle Scholar
  • 42 Agnelli G, George DJ, Kakkar AK , et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (7) 601-609
    CrossrefPubMedGoogle Scholar
  • 43 Zwicker JI, Liebman HA, Bauer KA , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 2013; 160 (4) 530-537
    CrossrefPubMedGoogle Scholar
  • 44 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 45 Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110 (5) 1149-1161
    CrossrefPubMedGoogle Scholar
  • 46 Smorenburg SM, Hettiarachchi RJ, Vink R, Büller HR. The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost 1999; 82 (6) 1600-1604
    PubMedGoogle Scholar
  • 47 Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Büller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82 (2) 947-952
    PubMedGoogle Scholar
  • 48 Lebeau B, Chastang C, Brechot JM , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994; 74 (1) 38-45
    CrossrefPubMedGoogle Scholar
  • 49 Altinbas M, Coskun HS, Er O , et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2 (8) 1266-1271
    CrossrefPubMedGoogle Scholar
  • 50 Kakkar AK, Levine MN, Kadziola Z , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22 (10) 1944-1948
    CrossrefPubMedGoogle Scholar
  • 51 Klerk CP, Smorenburg SM, Otten HM , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23 (10) 2130-2135
    CrossrefPubMedGoogle Scholar
  • 52 van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29 (15) 2071-2076
    CrossrefPubMedGoogle Scholar
  • 53 Lee AY, Rickles FR, Julian JA , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23 (10) 2123-2129
    Google Scholar